Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company dedicated to developing TELOMIR-1, a novel small molecule designed to elongate DNA's protective telomere caps. This approach aims to enhance the fidelity of DNA replication, potentially reversing cellular aging and addressing age-related inflammatory conditions such as hemochromatosis and osteoarthritis. By promoting telomere lengthening, TELOMIR-1 seeks to protect stem cells and sustain their self-renewal capabilities, offering a promising therapeutic intervention for age-associated diseases. Founded in 2021 and headquartered in Miami, Florida, Telomir Pharmaceuticals is committed to advancing longevity science through innovative treatments that target the fundamental mechanisms of aging.